# Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis

> **NCT01093885** · NA · COMPLETED · sponsor: **University of Pennsylvania** · enrollment: 15 (actual)

## Conditions studied

- Systemic Sclerosis
- Scleroderma

## Interventions

- **DRUG:** Ambrisentan

## Key facts

- **NCT ID:** NCT01093885
- **Lead sponsor:** University of Pennsylvania
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2018-11-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01093885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01093885, "Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01093885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*